The company said, “Consistent with the Company’s long term growth algorithm, it currently expects 2025 Organic Sales Growth to outpace the weighted average growth in the categories and countries it competes, which are currently growing at approximately two percent. Reported Net Sales are forecast to reflect a negative impact of approximately 300 basis points from currency translation as well as a negative 240 basis point impact from a combination of its PPE divestiture and the exit of the company’s private label diaper businesses in the US. Adjusted Operating Profit is expected to grow at a high single-digit rate on a constant-currency basis including a negative 320 basis point impact from a combination of its PPE divestiture and the exit of the company’s private label diaper businesses in the US. Operating Profit growth is also expected to be negatively impacted by approximately 300 basis points from currency translation. Adjusted Earnings Per share are expected to grow at a mid-to-high single-digit rate on a constant-currency basis including a negative 320 basis point impact from a combination of its PPE divestiture and the exit of the company’s private label diaper businesses in the US as well as a negative 100 basis point impact from items below operating profit including an impact from higher net interest expense, a higher effective adjusted tax rate and lower shares outstanding, among others. Earnings Per Share are also currently expected to be negatively impacted by approximately 350-400 basis points from currency translation, including the impact on income from equity interests.”
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KMB:
- Notable companies reporting before tomorrow’s open
- KMB Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Kimberly-Clark price target lowered to $132 from $144 at Barclays
- Kimberly-Clark price target lowered to $132 from $151 at UBS
- Kimberly-Clark price target lowered to $124 from $140 at JPMorgan